XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
April 25, 2024
April 25, 2024
April 23, 2024
April 23, 2024
April 19, 2024
April 18, 2024
April 16, 2024
April 11, 2024
April 11, 2024
April 11, 2024
April 11, 2024
April 11, 2024
April 11, 2024
April 11, 2024
April 11, 2024
April 8, 2024